A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

February 27, 2020

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions
Parkinson Disease
Interventions
DRUG

NLY01

exenatide and polyethylene glycol (PEG)

DRUG

Vehicle

Saline (Sodium Chloride)

Trial Locations (61)

10017

NYU Langone Medical Center, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, New York

10032

Neurological Institute, Columbia University Medical Center, New York

19107

University of Pennsylvania, Philadelphia

20007

Georgetown University Hospital, Washington D.C.

21201

University of Maryland, Neurology Ambulatory Center, Maryland Parkinson's Disease and Movement Disorder Center, Baltimore

21287

Johns Hopkins University School of Medicine, Baltimore

22908

University of Virginia, Charlottesville

27157

Wake Forest Baptist Health Sciences, Winston-Salem

27599

UNC CTRC, Chapel Hill

27607

Raleigh Neurology, Raleigh

27705

Duke University Medical Center, Durham

30033

NeuroStudies, Decatur

30912

Augusta University, Augusta

32159

Charter Research, Winter Park

32224

Mayo Clinic Florida, Jacksonville

32608

University of Florida, Gainesville

33024

Infinity Clinical Research, Hollywood

33133

Visionary Investigators Network, Miami

33136

University of Miami, Miami

33486

Parkinson's Disease and Movement Disorder Center, Boca Raton

33613

University of South Florida, Tampa

34209

Nova Clinical Research, Bradenton

34470

Renstar Medical Research, Ocala

35233

University of Alabama at Birmingham, Birmingham

43210

The Ohio State University Wexner Medical Center, Columbus

43614

University of Toledo, Gardner-McMaster Parkinson Center, Toledo

44106

University Hospitals Cleveland Medical Center, Cleveland

48109

University of Michigan Hospital, Ann Arbor

48322

Henry Ford West Bloomfield Hospital, West Bloomfield

48334

Quest Research Institute, Farmington Hills

53226

Froedtert Hospital, Milwaukee

55414

University of Minnesota Delaware Clinical Research Unit, Minneapolis

55427

Struthers Parkinson's Center, Golden Valley

60611

Northwestern Medical Group Neurology Clinic, Chicago

60612

Rush University Medical Center, Chicago

62702

SIU Medicine, Springfield

66160

University of Kansas Medical Center, Kansas City

72205

University of Arkansas for Medical Sciences, Little Rock

74136

The Movement Disorder Clinic of Oklahoma, Tulsa

77030

Baylor College of Medicine, Houston

80113

Rocky Mountain Movement Disorder Center, Englewood

80204

University of Colorado, Denver

85013

St. Joseph's Hospital and Medical Center - Barrow Neurological Institute, Phoenix

85258

Movement Disorders Center, Scottsdale

85259

Mayo Clinic Arizona, Mayo Clinic Scottsdale, Scottsdale

85351

Banner Sun Health Research Institute, Sun City

90033

Keck School of Medicine of USC/University of Southern California, Los Angeles

90095

University of California, Los Angeles, Center for Neurotherapeutics, Los Angeles

91105

SC3 Research, Pasadena

92697

University of California, Irvine, Irvine

94143

University of California, San Francisco, San Francisco

95816

University of California Davis Health, Sacramento

97239

Oregon Health and Science University, Portland

98034

Booth Gardner Parkinson's Care Center, Kirkland

06510

Institute for Neurodegenerative Disorders, New Haven

02114

Massachusetts General Hospital Clinical Trials Pharmacy, Boston

02118

Boston University Medical Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

07764

Neurology Specialists of Monmouth County, West Long Branch

02903

Rhode Island Hospital, Providence

M5T 2S8

Toronto Western Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neuraly, Inc.

INDUSTRY

NCT04154072 - A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease | Biotech Hunter | Biotech Hunter